Glucocorticoids combined with tofacitinib in the treatment of Castleman’s disease:A case report  

作　　者：Xiao-Rui Liu Mei Tian 

机构地区：[1]Department of Rheumatology and Immunology,Affiliated Hospital of Zunyi Medical University,Zunyi 563003,Guizhou Province,China

出　　处：《World Journal of Clinical Cases》2022年第29期10794-10802,共9页世界临床病例杂志

摘　　要：BACKGROUND Castleman’s disease(CD),also known as vascular follicular lymphadenopathy is a rare proliferative disease of lymphoid tissue of unknown etiology that is clinically classified as unicentric CD(UCD) or multicentric CD(MCD) depending on lymph node involvement.At present,idiopathic MCD(iMCD) is treated with interleukin-6 inhibitors,but some patients have poor clinical outcomes.This paper reports on a case of iMCD that achieved a good therapeutic effect after treatment with glucocorticoids combined with tofacitinib.The relevant data are summarized and reported below.CASE SUMMARY This paper reports on a case of MCD in a 49-year-old female with persistent peritoneal effusion as the first manifestation and combined with multiple lymphadenopathies.Lymph node biopsy showed Castleman’s disease-like changes.The ascites subsided after treatment with glucocorticoids and tofacitinib,indicating that the treatment was effective.CONCLUSION The combination of glucocorticoids with tofacitinib is an effective regimen for the treatment of CD.

关 键 词：Castleman’s disease Multicentric Castleman’s disease Idiopathic multicentric Castleman’s disease Abdominal dropsy Tofacitinib GLUCOCORTICOIDS Case report 

分 类 号：R551.2[医药卫生—血液循环系统疾病]